Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD1901 18FES-PET receptor occupancy study in metastatic breast cancer
NL-OMON45904Phase 1Active, not recruiting
- Sponsor
- Radius Pharmaceuticals, Inc.
- Start
- Feb 2016
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of elacestrant in breast cancer, sponsored by Radius Pharmaceuticals, Inc. Primary endpoint: Effect of RAD1901 on ER expression and estradiol binding. Started Feb 2016; status: active, not recruiting.
02
Drugs
elacestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON45904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45904.